Vivo Capital

Vivo Capital is a prominent global investment firm exclusively dedicated to the healthcare sector, boasting approximately $5.8 billion in assets under management. Established in 1996, the firm has cultivated a deep and extensive track record in identifying and nurturing innovative companies across the entire healthcare continuum. With a strategic presence in key global healthcare hubs, including Palo Alto, Beijing, Shanghai, and Taipei, Vivo Capital leverages its international network and profound industry expertise to support its portfolio companies.

The firm's investment strategy is remarkably broad, spanning from early-stage ventures to late-stage public companies. Vivo Capital actively invests in a diverse array of healthcare sub-sectors, including biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. This comprehensive approach allows them to capture opportunities at various points of a company's lifecycle, providing capital and strategic guidance tailored to specific needs. Their commitment to the sector is underscored by significant capital raises, such as their Vivo Capital Fund X, which closed at $1.4 billion in 2021, demonstrating robust investor confidence in their specialized approach.

Vivo Capital is known for its hands-on approach, often partnering with management teams to drive growth and achieve significant milestones. They typically seek to make substantial investments that can meaningfully impact a company's trajectory. While specific first check sizes can vary widely depending on the stage and opportunity, their typical initial commitments range from approximately $5 million for promising early-stage opportunities to over $100 million for more mature, growth-oriented companies or public market investments. This flexibility, combined with their deep domain knowledge and global reach, positions Vivo Capital as a significant and influential investor in the global healthcare landscape.